📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-06 19:59
351 analysed today
FollowTelegram
351
Today
149,752
All-time analysed
42,937
Positive
6,664
Negative
91,466
Neutral
8,617
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
30 announcements match the current filters (relevance ≥ 5).
15% Sales Growth in Q1 FY27; Innovation Portfolio Reaches 7.5% of Revenue
GSK India reported a strong Q1 FY2027 with 15% sales growth, outperforming the Indian pharmaceutical industry's 13.5% growth. The 'Freshness Index' (products launched in the last 3 years) now contributes 7.5% to the top line, driven by specialty respiratory and oncology drugs. Despite a 36% spike in operating expenses due to front-loaded marketing for new launches, EBITDA grew 17%, slightly faster than sales. Management expects EBITDA margins to normalize to approximately 34% for the full year as spending stabilizes.
Confidence: HIGH
What changedThe company has successfully transitioned to an innovation-led growth model, with new specialty products now contributing 7.5% of revenue compared to near-zero three years ago.
Why it mattersHigh-margin specialty products and adult vaccines are reducing dependence on price-controlled NLEM products, structurally improving the company's profitability profile and growth potential.
Sales Growth (Q1 FY27): 15%EBITDA Growth (Q1 FY27): 17%Innovation Portfolio Contribution: 7.5%Shingrix Growth: 60-65%Target EBITDA Margin: 34%Nucala Active Patients: 600
📅 Short termPositive sentiment is expected as the company outperformed the industry growth rate and showed strong traction in high-margin specialty segments.
📈 Long termStructural shift towards specialty biopharma and vaccines could lead to higher sustainable margins and reduced regulatory risk over the next 3-5 years.
⚠ Risk flags
- High marketing spend requirements for new launches
- Regulatory price controls on the base General Medicines portfolio
- Execution risk in scaling the oncology segment
Key Highlights
Sales grew by 15% in Q1 FY27, exceeding the Indian pharmaceutical industry growth of 13.5%
The innovation portfolio (products launched within 3 years) contributed 7.5% to total revenue
Shingrix (adult vaccine) recorded a growth of 60-65% during the quarter
Nucala (respiratory) active patient base reached 600, nearly doubling the business year-on-year
Operating expenses increased by 36% due to deliberate front-loading of marketing activities for new launches
👀 What to Watch
Monitor the sustainability of the 15% growth rate and the margin normalization to 34% as marketing spends stabilize. Watch for the continued ramp-up of the oncology portfolio (Jemperli and Zejula) as a key high-margin driver.
₹52 Cr Tax Refund Received for AY 1984-85; ₹42.09 Cr Interest to Boost P&L
GlaxoSmithKline Pharmaceuticals (GSK) has received a tax refund of ₹52.00 Cr pertaining to the Assessment Year 1984-85. A significant portion of this, ₹42.09 Cr, is interest income that will be credited directly to the P&L account as income. This interest component represents approximately 4.06% of the company's TTM PAT of ₹1,036 Cr. While the refund relates to a 40-year-old legacy matter, the cash inflow and one-time P&L gain are positive for the current fiscal year's liquidity and earnings.
Confidence: HIGH
What changedA legacy tax dispute from 1984-85 has been resolved, resulting in a cash refund and the recognition of substantial interest income.
Why it mattersThe settlement provides a one-time boost to the bottom line (approx. 4% of annual PAT) and improves the cash position, though it does not reflect operational performance changes.
Total Refund Received: ₹52.00 CrInterest Income (P&L Credit): ₹42.09 CrInterest vs TTM PAT: 4.06%Assessment Year: 1984-85Demand Liability Mentioned: ₹23.21 Cr
📅 Short termThe stock may see positive sentiment in the short term due to the cash inflow and the expected boost to the next quarterly profit report.
📈 Long termLimited structural impact as this is a non-recurring legacy settlement and does not affect the company's core pharmaceutical business or oncology growth strategy.
⚠ Risk flags
- One-off nature of income
- Legacy litigation risk
Key Highlights
Total tax refund of ₹52.00 Cr received in the bank account on August 6, 2026.
Interest income of ₹42.09 Cr to be recognized in the P&L account, providing a one-time earnings boost.
The refund pertains to a long-standing tax dispute from Assessment Year 1984-85.
Final Order from ACIT Cir 7(1)(1) also noted a demand liability of ₹23.21 Cr, though the net result was a refund.
👀 What to Watch
Investors should note this as a non-recurring gain in the upcoming quarterly results. It is important to adjust for this ₹42.09 Cr one-time income when analyzing the company's core operational growth and margins.
GSK India Q1 PAT ₹237 Cr; MD Bhushan Akshikar re-appointed for 2 years
GlaxoSmithKline Pharmaceuticals (GSK India) reported a 16.5% YoY increase in consolidated revenue to ₹938.44 Cr for Q1 FY27. Consolidated PAT rose 15.7% YoY to ₹237.18 Cr, reflecting steady operational performance. The board has re-appointed Mr. Bhushan Akshikar as Managing Director for a two-year term starting December 1, 2026, ensuring leadership continuity. Additionally, Ms. Karine J F Natland, who leads GSK's global General Medicines portfolio (contributing >30% of global sales), joins the board as a Non-Executive Director.
Confidence: HIGH
What changedRe-appointment of the Managing Director for a two-year term and the induction of the SVP Asia Pacific (General Medicines) to the Board of Directors.
Why it mattersEnsures leadership stability for the next two years and provides the Indian entity with direct strategic alignment with GSK's global General Medicines division, which drives 80-85% of local business.
Q1 Consolidated Revenue: ₹938.44 CrQ1 Consolidated PAT: ₹237.18 CrYoY Revenue Growth: 16.5%MD Re-appointment Term: 2 yearsGlobal GenMed Sales Contribution: >30%
📅 Short termThe stock may react positively to the double-digit YoY growth in both revenue and profit, coupled with the removal of leadership uncertainty.
📈 Long termLeadership continuity and closer board-level integration with global APAC strategy support the company's shift toward high-margin specialty drugs and vaccines.
⚠ Risk flags
- Dependency on CMOs for supply chain stability
- NLEM price controls impacting revenue growth
Key Highlights
Consolidated Revenue for Q1 FY27 grew 16.5% YoY to ₹938.44 Cr from ₹805.17 Cr
Consolidated Net Profit for the quarter reached ₹237.18 Cr compared to ₹205.01 Cr in the previous year
MD Bhushan Akshikar re-appointed for a 2-year term effective December 1, 2026
New Director Karine J F Natland leads a global portfolio contributing >30% of GSK's global sales
Standalone EPS for the quarter stood at ₹14.95, up from ₹12.08 YoY
👀 What to Watch
Monitor the scaling of the newly launched Oncology portfolio (Jemperli and Zejula) and the growth of the Shingrix vaccine under the extended leadership of the Managing Director.
GSK India Q1 FY27: 16.5% Revenue Growth to ₹938 Cr; MD Re-appointed for 2 Years
GlaxoSmithKline Pharmaceuticals (GSK India) reported a strong start to FY27 with consolidated revenue growing 16.5% YoY to ₹938.44 Cr. Consolidated PAT increased by 15.7% YoY to ₹237.18 Cr, while standalone EPS rose to ₹14.95 from ₹12.08. The board has also ensured leadership continuity by re-appointing Mr. Bhushan Akshikar as Managing Director for a two-year term starting December 2026 and inducting Ms. Karine J F Natland, a global GSK leader, to the board.
Confidence: HIGH
What changedGSK India reported its Q1 FY27 financial results showing double-digit growth and confirmed the re-appointment of its Managing Director along with a change in its Non-Executive board composition.
Why it mattersThe results indicate strong volume-led growth despite pricing pressures from NLEM. The induction of a global leader (Karine Natland) who oversees 30% of GSK's global sales suggests a strategic focus on aligning the Indian General Medicines portfolio with global growth engines.
Consolidated Revenue (Q1 FY27): ₹938.44 CrConsolidated PAT (Q1 FY27): ₹237.18 CrYoY Revenue Growth: 16.5%YoY PAT Growth: 15.7%Standalone EPS (Q1 FY27): ₹14.95
📅 Short termThe stock is likely to react positively to the double-digit growth in both revenue and profit, which exceeds the historical TTM growth rates.
📈 Long termLeadership continuity and the strategic shift toward high-margin specialty drugs and vaccines (Shingrix) support the company's goal of 10%+ growth and high ROCE sustainability.
⚠ Risk flags
- Pricing controls on NLEM-covered products
- Dependency on Contract Manufacturing Organizations (CMOs) for supply stability
Key Highlights
Consolidated revenue from operations grew 16.5% YoY to ₹938.44 Cr in Q1 FY27.
Consolidated Profit After Tax (PAT) increased 15.7% YoY to ₹237.18 Cr.
Standalone EPS improved to ₹14.95 compared to ₹12.08 in the same quarter last year.
Managing Director Bhushan Akshikar re-appointed for a 2-year term effective December 1, 2026.
Standalone other income includes a ₹18 Cr dividend from 100% subsidiary Biddle Sawyer Limited.
👀 What to Watch
Investors should monitor the sales trajectory of the newly launched Oncology portfolio (Jemperli and Zejula) and the scaling of the Shingrix vaccine, which are key to maintaining the current double-digit growth momentum.
GSK India Q1 Results: 16.5% Revenue Growth to ₹938 Cr; MD Re-appointed for 2 Years
GlaxoSmithKline Pharmaceuticals (GSK India) reported a solid Q1 FY27 with consolidated revenue rising 16.5% YoY to ₹938.44 Cr. Consolidated PAT increased 15.7% YoY to ₹237.18 Cr, maintaining strong profitability with an EPS of ₹14.95. The board ensured leadership continuity by re-appointing Bhushan Akshikar as Managing Director for a two-year term starting December 2026. Additionally, the appointment of Karine J F Natland (SVP APAC) to the board aligns the Indian entity closer to GSK's global General Medicines strategy.
Confidence: HIGH
What changedGSK India reported its Q1 FY27 financial results and confirmed leadership continuity with the MD's re-appointment and a new board member from the global leadership team.
Why it mattersThe 16.5% revenue growth exceeds the company's own expected growth rate of 10%+, demonstrating strong execution in the specialty and vaccine segments despite regulatory price caps on general medicines.
Q1 Consolidated Revenue: ₹938.44 CrQ1 Consolidated PAT: ₹237.18 CrYoY Revenue Growth: 16.5%YoY PAT Growth: 15.7%MD Re-appointment Term: 2 years
📅 Short termThe stock may react positively to the double-digit top-line and bottom-line growth, which provides comfort on the company's ability to navigate NLEM price controls.
📈 Long termThe re-appointment of the MD and the inclusion of the APAC head on the board suggest a stable strategic focus on high-margin innovative assets and vaccines over the next 2-3 years.
⚠ Risk flags
- Price controls on NLEM-covered products
- Dependency on Contract Manufacturing Organizations (CMOs)
Key Highlights
Consolidated revenue from operations grew 16.5% YoY to ₹938.44 Cr from ₹805.17 Cr.
Consolidated Net Profit for the quarter increased 15.7% YoY to ₹237.18 Cr.
Managing Director Bhushan Akshikar re-appointed for a 2-year term effective December 1, 2026.
New Director Karine Natland brings experience leading a global portfolio contributing >30% of GSK's global sales.
Standalone Other Income includes ₹18 Cr dividend from 100% subsidiary Biddle Sawyer Limited.
👀 What to Watch
Investors should monitor the growth trajectory of the newly launched Oncology portfolio (Jemperli and Zejula) and the scaling of the Shingrix vaccine, which are key to maintaining the current double-digit growth momentum.
15.7% YoY PAT Growth in Q1 FY27; MD Re-appointed for 2-Year Term
GlaxoSmithKline Pharmaceuticals (GSK India) reported a 16.5% YoY increase in consolidated revenue to ₹938.44 Cr for the quarter ended June 30, 2026. Consolidated Net Profit grew 15.7% YoY to ₹237.18 Cr, although it declined 14.6% sequentially from the preceding March quarter. The Board has re-appointed Bhushan Akshikar as Managing Director for a two-year term starting December 2026 and inducted Karine J F Natland (SVP APAC, GSK) as a Non-Executive Director.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and confirmed leadership continuity with the re-appointment of its Managing Director and a new board induction from the global GSK team.
Why it mattersThe double-digit YoY growth indicates strong volume performance in a market where pricing is often capped by regulation. Leadership continuity is vital as the company pivots toward high-margin specialty and oncology segments.
Consolidated Revenue (Q1 FY27): ₹938.44 CrConsolidated PAT (Q1 FY27): ₹237.18 CrYoY Revenue Growth: 16.5%YoY PAT Growth: 15.7%MD Re-appointment Term: 2 Years
📅 Short termThe stock may see positive sentiment due to healthy YoY growth and management stability, though the sequential (QoQ) dip in profits may temper immediate gains.
📈 Long termGSK India's structural shift toward innovative specialty drugs and vaccines (Shingrix) is expected to drive margin expansion and reduce reliance on price-controlled general medicines.
⚠ Risk flags
- NLEM price controls impacting revenue
- Dependency on third-party CMOs for supply chain stability
- High valuation (P/E of 43.3) relative to historical growth rates
Key Highlights
Consolidated Revenue from operations rose 16.5% YoY to ₹938.44 Cr from ₹805.17 Cr.
Consolidated PAT increased 15.7% YoY to ₹237.18 Cr compared to ₹205.01 Cr in the same quarter last year.
Managing Director Bhushan Akshikar re-appointed for a 2-year term effective December 1, 2026.
Other income for the quarter included a ₹18 Cr dividend received from 100% subsidiary Biddle Sawyer Limited.
Consolidated EBITDA margins remained healthy, with Profit Before Tax at ₹322.45 Cr (34.3% of revenue).
👀 What to Watch
Monitor the execution of the Oncology portfolio (Jemperli and Zejula) and the scaling of the Shingrix vaccine, as these innovative products are critical to offsetting NLEM-related pricing pressures.
24% PAT growth to ₹253 Cr in Q1FY27; Revenue up 15% to ₹924 Cr
GSK India delivered a strong Q1FY27 performance with Profit After Tax (PAT) rising 24% Y-o-Y to ₹253 crores. Revenue grew 15% Y-o-Y to ₹924 crores, driven by double-digit growth in core General Medicines and the scaling of the Oncology portfolio launched in August 2025. EBITDA margins remained healthy at 32%, supported by execution excellence and a favorable base effect. The company is also preparing for high-potential launches including Blenrep and the Arexvy vaccine.
Confidence: HIGH
What changedGSK India has successfully transitioned from previous supply chain disruptions to a period of strong double-digit growth in both revenue and profitability.
Why it mattersThe results validate the company's strategy to pivot toward innovative specialty drugs and adult vaccines, which typically offer higher margins and better protection against NLEM price controls.
Revenue (Q1FY27): ₹924 croresPAT (Q1FY27): ₹253 croresEBITDA Margin: 32%Quarterly Revenue vs TTM Revenue: ~24.2%Quarterly PAT vs TTM PAT: ~24.4%
📅 Short termThe stock is likely to react positively to the strong earnings beat and margin stability in the coming weeks.
📈 Long termThe structural shift toward Oncology and Adult Vaccines (Shingrix) provides a sustainable growth runway beyond traditional general medicines.
⚠ Risk flags
- NLEM price controls on essential medicines
- Execution risk for upcoming innovative product launches
Key Highlights
Revenue for Q1FY27 stood at ₹924 crores, representing a 15% Y-o-Y growth
Profit After Tax (PAT) increased by 24% to ₹253 crores compared to the same quarter last year
EBITDA margins were maintained at 32% for the quarter
Top five promoted brands in General Medicines outperformed the market with an Evolution Index (EI) > 100
Oncology therapies Jemperli and Zejula have shown significant growth since their August 2025 launch
👀 What to Watch
Watch for the commercial launch timelines of Blenrep and Arexvy, as these innovative products are critical for the company's long-term strategy to shift toward high-margin specialty segments.
15.7% YoY PAT Growth in Q1; MD Bhushan Akshikar Re-appointed for 2 Years
GlaxoSmithKline Pharmaceuticals (GSK India) reported a 16.5% YoY increase in consolidated revenue to ₹938.44 cr for Q1 FY27. Consolidated PAT grew 15.7% YoY to ₹237.18 cr, although it saw a sequential decline from the ₹277.86 cr reported in the preceding March quarter. The board has confirmed leadership continuity by re-appointing Bhushan Akshikar as Managing Director for a two-year term starting December 2026 and appointing Karine Natland, GSK's SVP for APAC, to the board.
Confidence: HIGH
What changedGSK India delivered double-digit YoY growth in Q1 FY27 and secured leadership stability with the MD's re-appointment and a new global representative on the board.
Why it mattersThe results demonstrate the company's ability to grow despite regulatory price controls (NLEM), while the management changes ensure continuity in the strategic shift toward high-margin specialty medicines.
Consolidated Revenue (Q1): ₹938.44 crConsolidated PAT (Q1): ₹237.18 crYoY Revenue Growth: 16.5%YoY PAT Growth: 15.7%Q1 Revenue vs TTM Revenue: 24.5%
📅 Short termThe stock may see positive sentiment due to healthy YoY growth and management stability, though sequential softening is typical for the pharmaceutical sector in Q1.
📈 Long termThe structural shift toward innovative specialty drugs and vaccines (Oncology and Shingrix) remains the key long-term value driver for this high-ROCE MNC pharma player.
⚠ Risk flags
- NLEM price controls impacting margins
- Dependency on Contract Manufacturing Organizations (CMOs) for supply
- Sequential decline in profitability
Key Highlights
Consolidated Revenue from operations increased 16.5% YoY to ₹938.44 cr from ₹805.17 cr.
Consolidated Net Profit rose 15.7% YoY to ₹237.18 cr compared to ₹205.01 cr in the year-ago period.
Standalone Other Income includes a ₹18 cr dividend received from 100% subsidiary Biddle Sawyer Limited.
Managing Director Bhushan Akshikar re-appointed for a 2-year term effective December 1, 2026.
Karine J F Natland, SVP Asia Pacific at GSK, inducted as a Non-Executive Director effective August 3, 2026.
👀 What to Watch
Investors should monitor the execution of the Oncology portfolio (Jemperli and Zejula) and the scaling of the Shingrix vaccine, which are expected to be primary growth drivers to offset NLEM-related price caps.
GSK India Q1 FY27: 15% Revenue Growth and 24% PAT Increase Driven by Innovation Portfolio
GSK India reported a strong Q1 FY27 with revenue growing 15% YoY to ₹924 crore and PAT increasing 24% to ₹253 crore. The growth was significantly bolstered by the 'Innovation' portfolio (Oncology, New Respiratory, and Adult Vaccines), which now accounts for 7% of total sales compared to 4% in the previous year. EBITDA margins expanded by 50 bps to 31.7%, driven by a 150 bps improvement in gross margins due to a favorable product mix. The company maintained a dominant 23% share in its represented market, with the Shingrix vaccine delivering 65% YoY growth.
Confidence: HIGH
What changedGSK India is successfully transitioning its portfolio mix toward high-margin innovative products, which are now contributing a larger share of growth and profitability.
Why it mattersThe shift toward specialty drugs and vaccines reduces the company's vulnerability to price controls on essential medicines and leverages its global R&D pipeline to sustain high ROCE (currently 61%).
Q1 FY27 Revenue: ₹924 crPAT Growth (YoY): 24%EBITDA Margin: 31.7%Innovation Portfolio Share: 7%Shingrix Growth: 65%EPS (Q1 FY27): ₹14.95
📅 Short termThe stock may see positive momentum as the earnings growth (24%) significantly outpaced revenue growth (15%), reflecting improved operational efficiency.
📈 Long termThe structural shift toward Oncology and Specialty medicines provides a long-term runway for margin expansion and premium positioning in the Indian pharma market.
⚠ Risk flags
- NLEM price caps on essential medicines
- Dependency on CMOs for supply chain stability
- High SG&A investment required for new product launches
Key Highlights
Revenue increased 15% YoY to ₹924 crore, while PAT grew 24% to ₹253 crore.
Innovation portfolio contribution rose to 7% of sales, driving 25% of the total headline growth.
Shingrix (Adult Vaccine) delivered 65% YoY growth through expanded HCP and HCO engagement.
Gross margins improved by 150 bps due to pricing and favorable product mix, offset slightly by higher SG&A.
Maintained a 23% market share in the represented market, with Vaccines leading at 26.1% share.
👀 What to Watch
Monitor the execution of the Oncology portfolio (Jemperli and Zejula) and the scaling of the adult vaccination market via Shingrix. Investors should also track the impact of NLEM price regulations on the General Medicines segment, which remains the core volume driver.
₹57 Dividend per Share Approved at 101st AGM; All Resolutions Passed with >99% Majority
GlaxoSmithKline Pharmaceuticals (GSK) concluded its 101st AGM on June 30, 2026, where shareholders officially approved a dividend of ₹57 per share for FY26. This represents a high payout ratio of approximately 93% against the TTM EPS of ₹61.15. All six resolutions, including the adoption of financial statements and commission to independent directors, were passed with near-unanimous support. The company maintains a strong balance sheet with a debt-to-equity ratio of 0.01 and a high ROCE of 61.0%.
Confidence: HIGH
What changedShareholders have officially ratified the FY26 financial results and the ₹57 per share dividend payout, alongside the re-appointment of Director Mr. Subesh Williams.
Why it mattersThe high dividend payout (93% of EPS) confirms GSK's status as a cash-generative MNC pharma play that prioritizes shareholder returns despite regulatory headwinds like NLEM price caps.
Dividend per share: ₹57Dividend Payout Ratio: ~93.2%Dividend Yield: ~2.38%Total valid votes for dividend: 14,24,89,055TTM EPS: ₹61.15
📅 Short termThe stock may see minor positive sentiment as the dividend is now officially approved and the record date/payment cycle proceeds.
📈 Long termThe company is structurally shifting toward high-margin specialty drugs and vaccines to offset NLEM price controls; long-term value depends on the successful scaling of these innovative assets.
⚠ Risk flags
- High payout ratio limits capital for large-scale inorganic expansion
- Pricing power limited by NLEM regulations
- Supply chain dependency on CMOs
Key Highlights
Approved a final dividend of ₹57 per equity share for the financial year ended March 31, 2026
Dividend resolution passed with 99.99% majority (14,24,89,055 votes in favor)
Adopted audited financial statements for FY26 with 100% of valid votes (14,23,62,550 votes)
Special resolution for commission to Independent Directors passed with 99.96% majority
Cut-off date for voting eligibility was June 23, 2026, with 1,32,132 total shareholders on record
👀 What to Watch
Investors should monitor the dividend credit timeline, typically within 30 days of the AGM. The focus remains on the execution of the new Oncology portfolio (Jemperli and Zejula) and the scaling of the Shingrix vaccine to drive double-digit growth.
GSK Pharma 101st AGM on June 30; Recommends ₹57 Dividend per Share
GlaxoSmithKline Pharmaceuticals Limited has scheduled its 101st Annual General Meeting for June 30, 2026, to approve a final dividend of ₹57 per equity share for FY 2025-26. The company has fixed May 29, 2026, as the record date for determining dividend eligibility. Key agenda items include the re-appointment of Director Subesh Williams and a special resolution to pay commissions to non-whole-time directors, capped at 1% of net profits. Additionally, the board seeks ratification for cost auditor fees of ₹8.02 lakhs for FY26 and ₹8.42 lakhs for FY27.
Key Highlights
Proposed final dividend of ₹57 per equity share for the financial year ended March 31, 2026.
Record date for dividend entitlement is fixed as Friday, May 29, 2026.
101st Annual General Meeting to be held via Video Conferencing on June 30, 2026.
Special resolution proposed for director commissions not exceeding 1% of net profits for 2026-2031.
Ratification of cost auditor remuneration of ₹8.02 Lakhs for FY26 and ₹8.42 Lakhs for FY27.
👀 What to Watch
Investors seeking the ₹57 dividend should ensure they hold the shares before the record date of May 29, 2026. Shareholders should also review the special resolution regarding director commissions before voting at the AGM.
GSK Pharma FY26 PAT Crosses ₹1,000 Cr Milestone; Declares ₹57 Dividend per Share
GlaxoSmithKline Pharmaceuticals reported a steady FY26 with a 10% PAT growth, crossing the ₹1,000 crore milestone for the first time. While revenue growth was muted at 2% due to supply chain disruptions from a CMO fire, EBITDA margins expanded significantly by 290 bps to 34%. The company's innovative portfolio, including Shingrix and oncology assets, now contributes 6% to the top-line, signaling a successful shift toward specialty medicines. A final dividend of ₹57 per share was declared, supported by a strong cash position of ₹2,745 crores and a robust ROCE of 61%.
Key Highlights
Full-year PAT excluding exceptionals crossed ₹1,000 crores for the first time, growing 10% YoY.
EBITDA margins improved sharply to 34% for FY26, an expansion of 290 basis points over the previous year.
Innovative and specialty portfolio contribution reached 6% of total revenue, led by Shingrix, Zejula, and Jemperli.
Board recommended a final dividend of ₹57 per share; year-end cash position remains strong at ₹2,745 crores.
Pediatric vaccines grew 9% while the adult vaccine segment continues to scale through new cardiovascular-metabolic strategies.
👀 What to Watch
Investors should take note of the significant margin expansion and the increasing revenue share of high-margin innovative products. The stock remains a strong defensive play given the high dividend payout and superior return ratios like the 61% ROCE.
GSK India FY26 PAT Rises 10% to ₹1012 Cr; Recommends ₹57 Final Dividend
GlaxoSmithKline Pharmaceuticals reported a 10% growth in annual Profit After Tax (PAT) to INR 1012 crores for FY 2025-26, despite a modest 2% revenue growth to INR 3790 crores. The company achieved significant margin expansion, with full-year EBITDA margins rising 290 basis points to 34%. A final dividend of Rs. 57 per equity share has been recommended by the Board. While supply chain disruptions impacted topline growth, the company saw strong performance in its Oncology and Vaccines portfolios, including the successful scale-up of Shingrix.
Key Highlights
Full-year Profit After Tax (PAT) increased by 10% to INR 1012 crores on revenue of INR 3790 crores.
EBITDA margins expanded by 290 bps to 34% for the full year and reached 35% in Q4.
Recommended a final dividend of Rs. 57 per equity share for the year ended 31st March 2026.
Oncology portfolio strengthened with Jemperli's first-line approval for endometrial cancer and market authorization for Blenrep.
General Medicines portfolio brands like Augmentin and Calpol grew ahead of the market with an Evolution Index (EI) over 100.
👀 What to Watch
Investors should note the strong margin expansion and the company's strategic shift towards high-value innovative therapies in Oncology and Vaccines. The healthy dividend payout and focus on supply chain resilience provide a positive outlook for long-term stability.
GSK Pharma FY26 PAT Crosses ₹1,000 Cr Milestone; Declares ₹57 Dividend per Share
GlaxoSmithKline Pharmaceuticals Limited (GSK India) reported a steady FY26 with revenue of ₹3,790 crore, up 2% YoY. A significant milestone was achieved as PAT (before exceptionals) crossed the ₹1,000 crore mark for the first time, reaching ₹1,010 crore with a 10% growth. Profitability saw a sharp rise with EBITDA margins expanding by 290 bps to 34.3%, driven by a shift toward an innovative portfolio and cost efficiencies. The company maintains a robust balance sheet with a cash position of ₹2,746 crore and an ROCE of 61.3%.
Key Highlights
FY26 PAT (before exceptional items) grew 10% YoY to ₹1,010 crore, the first time crossing the ₹1,000 crore threshold.
EBITDA margins expanded significantly by 290 bps to 34.3% for the full year, with Q4 margins reaching 35.1%.
The innovation portfolio (Oncology, Shingrix, New Respiratory) now contributes 6% to total sales, with Shingrix Rx growing 56% YoY.
Declared a final dividend of ₹57 per share for FY26, reflecting strong cash generation and a 45.1% return on net worth.
Maintained market leadership in key brands like Calpol and Augmentin, with the private vaccine market share at 20.9%.
👀 What to Watch
Investors should focus on the company's successful margin expansion and the increasing contribution of high-margin specialty and innovation products. The stock remains a high-quality play with strong capital efficiency (61% ROCE) and attractive dividend payouts.
GSK Pharma FY26 Net Profit Rises 11.7% to ₹1,036 Cr; Recommends ₹57 Dividend
GlaxoSmithKline Pharmaceuticals reported a steady performance for FY26, with consolidated revenue growing to ₹3,821.67 crore from ₹3,749.21 crore in the previous year. The company's net profit increased by 11.7% to ₹1,035.98 crore, bolstered by operational efficiencies and exceptional gains from property sales. A significant final dividend of ₹57 per share has been recommended, with a record date of May 29, 2026. The company maintains a robust balance sheet with cash and cash equivalents doubling to ₹1,102.05 crore.
Key Highlights
Consolidated Net Profit for FY26 grew 11.7% YoY to ₹1,035.98 crore
Board recommended a final dividend of ₹57 per equity share for FY26
Revenue from operations increased to ₹3,821.67 crore vs ₹3,749.21 crore in FY25
Cash and cash equivalents surged to ₹1,102.05 crore from ₹538.85 crore YoY
Exceptional credit of ₹20.62 crore recorded from the sale of surplus residential and land assets
👀 What to Watch
Investors should note the high dividend payout and the company's strong cash position, making it a stable defensive pick. The record date for the ₹57 dividend is May 29, 2026.
GSK Pharma FY26 PAT Rises 11.7% to ₹1,036 Cr; Recommends ₹57 Final Dividend
GlaxoSmithKline Pharmaceuticals reported a steady performance for FY26, with consolidated revenue growing to ₹3,821.67 crore from ₹3,749.21 crore in the previous year. The annual profit after tax saw a healthy increase of 11.7% to reach ₹1,035.98 crore, supported by operational efficiencies and exceptional gains from property sales. A significant highlight for shareholders is the recommendation of a final dividend of ₹57 per share, reflecting the company's strong cash position. The company's cash and cash equivalents nearly doubled during the year to ₹1,102.05 crore.
Key Highlights
Consolidated Revenue for FY26 increased to ₹3,821.67 crore compared to ₹3,749.21 crore in FY25
Net Profit (PAT) for the full year grew by 11.7% YoY to ₹1,035.98 crore
Board recommended a final dividend of ₹57 per equity share on a face value of ₹10
Cash and cash equivalents surged to ₹1,102.05 crore from ₹538.85 crore in the previous year
Exceptional gain of ₹20.62 crore recorded from the sale of surplus residential and non-operational land
👀 What to Watch
Investors should view the high dividend payout and robust cash reserves as a sign of financial strength and stability. The stock remains a solid defensive pick in the pharmaceutical sector with consistent earnings growth.
GSK Pharma FY26 PAT Rises 12% to ₹1,036 Cr; Recommends ₹57 Dividend per Share
GlaxoSmithKline Pharmaceuticals reported a steady financial performance for FY26, with consolidated Net Profit rising 11.7% to ₹1,035.98 crore compared to ₹927.58 crore in the previous year. The company's revenue from operations grew to ₹3,821.67 crore, supported by a strong cash position which doubled to ₹1,102.05 crore. A significant final dividend of ₹57 per share has been recommended, representing a high payout ratio. The record date for the dividend entitlement is fixed for May 29, 2026.
Key Highlights
Recommended a final dividend of ₹57 per equity share of face value ₹10 each.
Consolidated Profit After Tax (PAT) for FY26 stood at ₹1,035.98 crore vs ₹927.58 crore YoY.
Annual Revenue from Operations increased to ₹3,821.67 crore from ₹3,749.21 crore.
Cash and cash equivalents surged to ₹1,102.05 crore from ₹538.85 crore in the previous year.
Record date for dividend entitlement is May 29, 2026, with payment starting July 1, 2026.
👀 What to Watch
Investors seeking dividend income should ensure holdings are in their demat account by the May 29 record date to qualify for the ₹57 payout. The company's strong cash position and steady earnings growth support its status as a defensive healthcare play.
GSK Pharma Declares Rs 57 Dividend; FY26 Consolidated Net Profit Rises 11.7% to Rs 1,036 Crore
GlaxoSmithKline Pharmaceuticals has recommended a final dividend of Rs 57 per share for FY26, marking an increase from the Rs 54 total dividend paid in the previous fiscal. The company reported a steady financial performance with consolidated revenue growing to Rs 3,821.7 crore. Net profit for the year rose by 11.7% to Rs 1,036 crore, driven by operational growth and exceptional gains from property sales. The company remains debt-free with a significantly strengthened cash position of Rs 1,102 crore.
Key Highlights
Recommended a final dividend of Rs 57 per equity share for the financial year ended March 31, 2026.
Consolidated Net Profit for FY26 increased 11.7% YoY to Rs 1,035.98 crore from Rs 927.58 crore.
Annual Revenue from operations grew to Rs 3,821.67 crore compared to Rs 3,749.21 crore in FY25.
Cash and cash equivalents more than doubled to Rs 1,102.05 crore from Rs 538.85 crore YoY.
The company fixed May 29, 2026, as the record date for determining dividend eligibility.
👀 What to Watch
Investors seeking steady income should note the high dividend payout and the company's robust cash position. The consistent profit growth and debt-free balance sheet reinforce its status as a strong defensive pick in the pharma sector.
GSK Pharma Shareholders Approve Ronojit Biswas as Director and CFO with Over 99% Votes
GlaxoSmithKline Pharmaceuticals Limited has announced the successful passage of two ordinary resolutions via postal ballot. Shareholders overwhelmingly approved the appointment of Mr. Ronojit Biswas as a Director and as a Whole-time Director & Chief Financial Officer (CFO). Both resolutions received over 99.6% approval from the total votes cast, indicating strong shareholder confidence. The promoter group, which holds a significant stake, voted entirely in favor of the appointments.
Key Highlights
Appointment of Mr. Ronojit Biswas as Director approved with 99.69% of valid votes cast.
Appointment of Mr. Ronojit Biswas as Whole-time Director & CFO approved with 99.76% of valid votes cast.
Total voter turnout represented 84.04% of the total outstanding shares, with 142.37 million votes polled.
Promoter and Promoter Group (127.05 million shares) voted 100% in favor of both resolutions.
Public institutional support was high, with over 97% of institutional votes cast in favor of the appointments.
👀 What to Watch
This is a routine management update confirming the formalization of the CFO's role. Investors should continue to monitor the company's financial execution under the confirmed leadership.
GSK Pharma CFO Juby Chandy Resigns to Take Global Role Effective March 11, 2026
GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Mr. Juby Chandy from his dual roles as Whole-Time Director and Chief Financial Officer. The resignation became effective at the close of business hours on March 11, 2026. This management change is driven by Mr. Chandy's internal promotion to Finance Head for the Asia Pacific region within the global GSK group. The company had previously notified the exchanges of this transition on March 2, 2026.
Key Highlights
Mr. Juby Chandy resigned as CFO and Whole-Time Director effective March 11, 2026
Transition is due to his new appointment as Finance Head for the Asia Pacific region at GSK
The official resignation letter was submitted to the Board on March 2, 2026
The company confirmed compliance with Regulation 30 of SEBI Listing Regulations
Mr. Chandy (DIN: 09530618) had served as a key member of the executive leadership team
👀 What to Watch
Investors should watch for the announcement of a new CFO to ensure continuity in financial strategy. Since this is an internal group promotion, it is unlikely to signal any underlying operational issues.
